Not Yet Recruiting
A Study Of SY-3505 Versus Crizotinib In First Line Treatment Of Patients With ALK-Positive NSCLC
NCT06254599
- Conditions
- Bronchial Neoplasms, Carcinoma, Bronchogenic, Carcinoma, Non-Small-Cell Lung, +8 more
- Locations
-
- Cancer Hospital, Chinese Academy of Medical Sciences Beijing, China